SmithKline Beecham Animal Health, et al.; Withdrawal of Approval of NADA's

Riepilogo

The Food and Drug Administration (FDA) is withdrawing approval of three new animal drug applications (NADA's) and those portions of a fourth NADA providing for the use of nitrofurazone solution drug products. This action is being taken at the written request of the sponsors. In a final rule published elsewhere in this issue of the Federal Register, FDA is amending the regulations by removing the entries which reflect approval of the NADA's.